Show simple item record

dc.contributor.authorNovello, Sen
dc.contributor.authorScagliotti, Gen
dc.contributor.authorSydorenko, Oen
dc.contributor.authorVynnychenko, Ien
dc.contributor.authorVolovat, Cen
dc.contributor.authorSchneider, Cen
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorMcCoy, Sen
dc.contributor.authorHei, Yen
dc.contributor.authorSpigel, Den
dc.date.accessioned2014-09-22T09:02:28Z
dc.date.available2014-09-22T09:02:28Z
dc.date.issued2014-08
dc.identifier.citationMotesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. 2014, 9 (8):1154-61 J Thorac Oncolen
dc.identifier.issn1556-1380
dc.identifier.pmid25157768
dc.identifier.doi10.1097/JTO.0000000000000227
dc.identifier.urihttp://hdl.handle.net/10541/326331
dc.description.abstractThe phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of thoracic oncology : official publication of the International Association for the Study of Lung Canceren
dc.titleMotesanib plus Carboplatin/Paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study.en
dc.typeArticleen
dc.contributor.department*Department of Oncology, University of Turin, San Luigi Hospital, Turin, Italy; †Thoracic Surgery Department, Zaporizhzhya State Medical University, Zaporizhzhya, Ukraine; ‡Sumy Regional Oncology Centre, Sumy State University, Sumy, Ukraine; §Centrul de Oncologie Medicala, Iasi, Romania; ‖Central Hospital Bad Berka, Bad Berka, Germany; ¶Department of Medical Oncology, The Christie National Health Services Foundation Trust, Manchester, United Kingdom; #Department of Biostatistics & Epidemiology, Amgen Inc., South San Francisco; **Department of Oncology, Amgen Inc., Thousand Oaks, CA; and ††Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN.en
dc.identifier.journalJournal of Thoracic Oncologyen
html.description.abstractThe phase 3 MONET1 study evaluated motesanib (a small-molecule inhibitor of vascular endothelial growth factor receptors) plus carboplatin/paclitaxel versus placebo plus carboplatin/paclitaxel as first-line therapy for advanced non-small-cell lung cancer (NSCLC). Treatment and enrollment of patients with squamous histology were permanently discontinued following higher early mortality and gross hemoptysis in those with squamous NSCLC who received motesanib. Enrollment of patients with nonsquamous histology was temporarily halted, but resumed following a protocol amendment (Scagliotti et al. J Clin Oncol. 2012;30:2829-2836). Herein, we report data from the squamous cohort.


This item appears in the following Collection(s)

Show simple item record